Quantcast

Sanofi Launches Phase 3 Trials To Evaluate Isatuximab In Multiple Myeloma


Shutterstock photo

(RTTNews.com) - Sanofi (SNYNF) announced the company has launched two new late-stage clinical studies to determine if isatuximab (an anti-CD38 antibody), when used in combination with other commonly used cancer treatments, might be an effective treatment option for certain people with multiple myeloma, a rare blood cancer.

IKEMA study is a 325-patient randomized, open-label, global multicenter Phase 3 trial that will compare isatuximab in combination with carfilzomib and dexamethasone against carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma that have previously been treated with one-to-three lines of therapy.

IMROZ study is a 425-patient randomized, open-label, global multicenter Phase 3 trial that will compare isatuximab in combination with bortezomib, lenalidomide and dexamethasone against bortezomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients not eligible for transplant.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com




This article appears in: World Markets , Stocks , Economy , Technology
Referenced Symbols: SNY


More from RTT News

Subscribe






See headlines for SNY









Research Brokers before you trade

Want to trade FX?